Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from CardieX ( (AU:CQT) ) is now available.
CONNEQT Health Limited has reported that all resolutions presented at its April Extraordinary General Meeting were passed by poll, reflecting strong shareholder support for the company’s strategic and capital initiatives. Key approvals included the issuance of convertible notes to C2 Ventures, related conversion shares and securities, ratification of a prior share placement, further share issues, and long-term incentive arrangements for senior executives and a director fee-equity swap.
These outcomes collectively bolster CONNEQT Health’s capital structure and provide additional flexibility to fund growth in its vascular health technology portfolio. The endorsement of equity and incentive measures also underpins management alignment with shareholders as the company seeks to expand its presence in the medical and home health device markets for cardiovascular and hypertension-related conditions.
More about CardieX
CONNEQT Health Limited is an Australian medical technology company focused on advancing vascular health to increase longevity. Its product suite includes medical and home health devices and digital solutions targeting hypertension, cardiovascular disease, and other vascular disorders, built on its SphygmoCor vascular biomarker technology and listed on the ASX under ticker CQT.
Average Trading Volume: 579,257
Technical Sentiment Signal: Sell
Current Market Cap: A$22.66M
See more data about CQT stock on TipRanks’ Stock Analysis page.